| __timestamp | Protagonist Therapeutics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1860000 | 5078000000 |
| Thursday, January 1, 2015 | 2963000 | 4717000000 |
| Friday, January 1, 2016 | 6961000 | 5096000000 |
| Sunday, January 1, 2017 | 11779000 | 4986000000 |
| Monday, January 1, 2018 | 13697000 | 4214000000 |
| Tuesday, January 1, 2019 | 15749000 | 3806000000 |
| Wednesday, January 1, 2020 | 18638000 | 3671000000 |
| Friday, January 1, 2021 | 27196000 | 3528000000 |
| Saturday, January 1, 2022 | 31739000 | 3445000000 |
| Sunday, January 1, 2023 | 33491000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Data in motion
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc., from 2014 to 2023.
Teva, a global leader, consistently reported higher SG&A expenses, peaking in 2016 with a staggering $5.1 billion. However, a notable decline of approximately 32% was observed by 2023, reflecting strategic cost management. In contrast, Protagonist Therapeutics, a burgeoning biotech firm, exhibited a steady increase in SG&A expenses, growing nearly 18-fold over the same period. This rise underscores their aggressive expansion and investment in innovation.
This juxtaposition highlights the contrasting strategies of an established giant and an emerging innovator, offering valuable insights into their operational priorities and market positioning.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited and United Therapeutics Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?